ArticleClinical pharmacology and therapeutics2026

Ten-Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme.

Chin Hang Yiu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.